China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced that its market filing for liraglutide, a Category 2.2 chemical drug, has been accepted for review by the National Medical Products Administration (NMPA). Hybio is now the only domestic firm to complete clinical trials via chemical synthesis and file for marketing of the product.
Drug Profile
Liraglutide is an analog of human glucagon-like peptide 1 (GLP-1), a key target for diabetes treatment. It has multiple physiological functions, including blood sugar-dependent insulin secretion promotion, pancreatic β-cell protection, delayed gastric emptying, and reduced appetite.
Market Context
Novo Nordisk’s originator is the only product commercially available globally. In China, sales of liraglutide have surged, reaching RMB 1.49 billion (USD 221.2 million) in 2021, up from RMB 150 million (USD 22.2 million) in 2013, with a 45% increase in 2021 compared to the previous year.-Fineline Info & Tech
